Low-dose tirzepatide meets composite endpoint in 62% of older Japanese adults

The wire

1. 01Among 37 adults aged 65 and older on tirzepatide at a maximum 5 mg/week, 23 (62.2%) met a composite of persistence, no adverse-event discontinuation and either 3% weight loss or 1.0-point HbA1c drop.
2. 02Median weight change was -3.07% and median HbA1c change -1.0 percentage point, with 51.4% reaching HbA1c below 7.0% and renal, hydration and nutritional markers generally stable.
3. 03The study was a single-center retrospective cohort with younger adults used only as overlap-weighted contextual comparators, so the low-dose strategy has not been tested prospectively.

From the source

Clinical Feasibility of a Low-Dose Tirzepatide Strategy in Older Adults with Type 2 Diabetes: Persistence, Metabolic Benefit, and Treatment Simplification in a Real-World Cohort

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026 Oct 15 · Kanazawa K, Hayashi K, Xinyi C et al.